Review Article
New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer
Table 1
Agents targeting AR in clinical development for CRPC.
| Drug | Mechanism of action | Patient characteristics | Phase of development | Clinical trial registration number |
| MDV-3100 | AR antagonist | Chemotherapy-treated | Phase III | NCT00974311 | | | Chemotherapy-naïve | Phase III | NCT01212991 | ARN-509 | AR antagonist | ND | Phase I-II | NCT01171898 | AZD3514 | AR antagonist | ND | Phase I-II | NCT01162395 | Abiraterone acetate | CYP 17 inhibitor | Chemotherapy-treated | Phase III | NCT00638690 | | | Chemotherapy-naïve | Phase III | NCT00887198 | Orteronel (TAK-700) | CYP 17 inhibitor | Chemotherapy-treated | Phase III | NCT01193257 | VN/124-1 (TOK-001) | AR downregulating agent, CYP 17 inhibitor, and AR antagonist | ND | Phase I-II | NCT00959959 |
|
|
ND: not defined.
|